Effectiveness of 7-
Conditions
Interventions
60 mg dexlansoprazole twice daily
1048 mg bismuth subsalicylate twice daily
500 mg tetracycline four times daily and
400 mg metronidazole three times daily
Probiotic was 37.5 mg Lactobacillus reuter
Active Comparator Drug,Active Comparator Drug
7-
day high-
dose PPI bismuth-
containing quadruple therapy ,14-
containing quadruple therapy
Sponsors
Thammasat University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Having abdominal pain which was indicative for assessing with esophagogastroduodenoscopy consistent with The Gastroenterological Association of Thailand(12) as followed; • Coexisting with dysphagia • Evidence of gastrointestinal blood loss such as previous history of bloody vomiting, melena and iron deficiency anemia • Unexplained weight loss such as unintended weight losing, recent diagnosis of diabetes mellitus or thyrotoxicosis • Persistent vomiting • Age onset of symptoms > 50 years old without any explainable causes including drugs and food • Progressive or recurrent symptoms after adequate medical treatments 2. Detecting for H. pylori infection with positive urease test and/or pathological findings of H. pylori and/or positive cultures 3. Having written informed consent for all participants.
Exclusion criteria
Exclusion criteria: 1. Any cases with upper gastrointestinal bleeding 2. Being treated with medications affecting the research outcome, for example, by using antibiotics including amoxicillin, clarithromycin, tetracycline or metronidazole within 1 month before the enrollment 3. Having contraindication to gastric biopsy such as coagulopathy 4. Any history of drug allergy for Tetracycline, Metronidazole, Bismuth, and Dexlansoprazole 5. Receiving proton pump inhibitor or receiving any antibiotics or bismuth within 4 weeks or consumption of probiotic products within 2 weeks. 6. Being pregnant or raising children with breast-feeding 7. Having history of H. pylori eradication treatment 8. Having severe underlying disease including end-stage renal disease requiring hemodialysis or peritoneal dialysis (GFR < 15), cirrhosis with Child-Pugh classification grade C, immunocompromised host with AIDS, malignancy and/or bed ridden cerebrovascular disease. 9. Any cases who receiving anticoagulant 10. Having previous gastric surgery 11. Unwilling to participate into research 12. Having history of taking previous medications which interacted with the research treatment 13. Having a medication that causes drugs to drugs interaction with a research medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effecitveness 4 weeks after intervention Helicobacter pylori eradication | — |
Secondary
| Measure | Time frame |
|---|---|
| Compare effectiveness of Helicobacter Pylori eradication 4 weeks after intervention Helicobacter pylori eradication | — |
Contacts
Public ContactPiyakorn Poonyam
Thammasat University
Outcome results
None listed